Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors
Publication year
2017Source
Future Oncology, 13, 2, (2017), pp. 185-194ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Oncology
Journal title
Future Oncology
Volume
vol. 13
Issue
iss. 2
Page start
p. 185
Page end
p. 194
Subject
Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health SciencesAbstract
Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase clinical trials novel systemic treatments are currently being evaluated to target both the well explored and novel emerging downstream effectors of KIT and PDGFRA signaling. Alternative therapeutic approaches also include exploring novel inhibitors of the KIT/PDGFRA receptors, immune checkpoint and cyclin-dependent kinase inhibitors. The final clinical trial outcome data for these agents are highly anticipated. Integration of new diagnostic techniques into routine clinical practice can potentially guide tailored delivery of agents in the treatment of a highly polyclonal, heterogeneous disease such as heavily pretreated advanced gastrointestinal stromal tumor.
This item appears in the following Collection(s)
- Academic publications [238441]
- Electronic publications [122525]
- Faculty of Medical Sciences [90373]
- Open Access publications [97520]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.